firstwordpharmaMarch 03, 2019
Tag: acadia , Neurocrine , Biotech Stocks
Needham analyst Alan Carr identified Acadia Pharmaceuticals and Neurocrine Biosciences as potential takeover targets among biotech firms, Investor's Business Daily reported Friday.
"There remains a consistent bias for later-stage companies," Carr remarked, adding "we continue to believe the main driver is the overlap in the supply of biotech companies with lower-risk assets and the disease focus strategy of pharma and big biotech."
The analyst noted that among 22 potential suitors, 18 have interest in immunotherapy-focused firms, while 17 are seeking companies with central nervous system assets.
Acadia markets the Parkinson's disease psychosis therapy Nuplazid, while Nuerocrine markets Ingrezza for tardive dyskinesia.
Carr said that Intercept Pharmaceuticals, which markets the liver disease therapy Ocaliva, could also be targeted in a takeover.
The analyst explained that of 58 biotechs to be acquired over the last five years, more than half had approved drugs, while 74 percent had generated late-stage data.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: